Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term

Zacks Investment Research highlights United Therapeutics (UTHR) as a potential long-term growth opportunity, despite its Zacks Rank #3 (Hold), citing a strong 'A' VGM Score and 'B' Growth Style Score. The company projects 10.4% year-over-year earnings growth, supported by recent upward analyst revisions for fiscal 2025, which raised the consensus estimate by $0.12 to $27.21 per share. This combination of robust growth metrics and positive earnings outlook positions UTHR as a noteworthy consideration for investors seeking long-term appreciation.

Analysis

United Therapeutics (UTHR) presents a mixed but compelling profile for growth-focused investors. While the stock holds a neutral Zacks Rank #3 (Hold), its underlying metrics suggest significant strength. The company is projected to deliver 10.4% year-over-year earnings growth for the current fiscal year, supported by a strong 'A' VGM Score and a 'B' Growth Style Score. This positive outlook is further substantiated by recent analyst activity, where two analysts revised fiscal 2025 earnings estimates upward within the last 60 days. This has lifted the Zacks Consensus Estimate for that period by $0.12 to $27.21 per share. Additionally, UTHR has a modest but consistent track record of beating earnings expectations, with an average positive surprise of 0.7%. The core investment thesis hinges on whether the strong forward-looking growth indicators and positive estimate revisions will outweigh the current neutral market rating.

Key Decisions for Investors

• Investors should consider UTHR as a potential addition to a growth-oriented portfolio, weighing the robust 10.4% earnings growth forecast against the neutral 'Hold' rating.
• Monitor future analyst estimate revisions closely, as the recent upward trend for fiscal 2025 could be a leading indicator of a potential ratings upgrade and improved market sentiment.
• Given the 'Hold' rank, a cautious approach may be warranted; a strategy could involve initiating a small position and waiting for further confirmation of fundamental strength or positive price momentum before increasing allocation.